Request Demo
Recent blog posts
Latest Hotspot
8 min read
Ibuprofen/Magnesium Oxide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Ibuprofen/Magnesium Oxide: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
ChiCTR2600127006 Blinatumomab Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into ChiCTR2600127006, evaluating Blinatumomab in Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
Meloxicam/Rizatriptan Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Meloxicam/Rizatriptan: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
NCT07658976 Doxycycline Hyclate HIV Infections Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07658976, evaluating Doxycycline Hyclate in HIV Infections: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07663903 Recombinant human coagulation factor VIII-Fc fusion protein (Gensciences) Hemophilia A Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07663903, evaluating Recombinant human coagulation factor VIII-Fc fusion protein (Gensciences) in Hemophilia A: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
Atezolizumab/Hyaluronidase-tqjs Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Atezolizumab/Hyaluronidase-tqjs: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
NCT07662395 Albumin-Bound Paclitaxel Diplopia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07662395, evaluating Albumin-Bound Paclitaxel in Diplopia: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
Nivolumab/Hyaluronidase-nvhy Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Nivolumab/Hyaluronidase-nvhy: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
NCT07663071 Retlirafusp alfa Locally Advanced Rectal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07663071, evaluating Retlirafusp alfa in Locally Advanced Rectal Carcinoma: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07662811 Enlonstobart Squamous non-small cell lung cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07662811, evaluating Enlonstobart in Squamous non-small cell lung cancer: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
JPRN-jRCT2041260070 Radiprodil Seizures Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into JPRN-jRCT2041260070, evaluating Radiprodil in Seizures: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07662122 BI-3034701 Obesity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07662122, evaluating BI-3034701 in Obesity: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.